# Treatment of Idiopathic Perifoveal Telangiectasia (IPT) With Open-Label Anecortave Acetate (15mg.).

> **NCT00211328** · PHASE2 · COMPLETED · sponsor: **Manhattan Eye, Ear & Throat Hospital** · enrollment: 5 (actual)

## Conditions studied

- Idiopathic Perifoveal Telangiectasia

## Interventions

- **DRUG:** anecortave acetate

## Key facts

- **NCT ID:** NCT00211328
- **Lead sponsor:** Manhattan Eye, Ear & Throat Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** —
- **Final completion:** 2007-03
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2009-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00211328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00211328, "Treatment of Idiopathic Perifoveal Telangiectasia (IPT) With Open-Label Anecortave Acetate (15mg.).". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00211328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*